Shanghai Medicilon, Inc.

Shanghai Medicilon, Inc. saw a significant intraday increase on March 24, 2026, contrasting with the broader market's performance. Despite recent declines over the week and month, the company has achieved substantial annual growth. Its market capitalization is CNY 7,306 million, with key financial metrics indicating challenges ahead.

Shanghai Medicilon, Inc. faced a notable decline today, with its stock dropping significantly. Over the past week and month, the company has experienced substantial downturns, contrasting with its previous year’s performance. Long-term metrics reveal ongoing challenges, including significant decreases over three and five years, raising concerns about its financial health.

Shanghai Medicilon, Inc. faced a notable decline in stock performance, reflecting ongoing challenges with significant drops over the past week and month. Despite a year-over-year increase, the company has struggled year-to-date and over the past three to five years, indicating potential financial instability and a lack of dividend yield.

Shanghai Medicilon, Inc. faced a notable decline today, with a 7.27% drop in stock price. Over the past week, the company has decreased by 16.09%, while its long-term performance shows significant declines over three and five years. Despite recent challenges, it has achieved a 71.4% increase over the past year.

Shanghai Medicilon, Inc. saw a notable decline in its stock price, contrasting with the broader market's performance. While the company has experienced impressive annual growth, its long-term outlook is challenging, marked by significant declines over three and five years. The company's financial metrics indicate a high dividend yield of 0.00% and negative return on equity.

Shanghai Medicilon, Inc. saw a notable decline in its stock today, contrasting with the broader market's performance. While the company has experienced positive year-to-date and annual growth, it faces challenges in long-term profitability, with net sales increasing but operating profit declining significantly over the past five years.

Shanghai Medicilon, Inc. has seen a significant stock increase today, contrasting with a decline in the broader market. Over the past year, the stock has risen substantially, outperforming the China Shanghai Composite. However, the company faces long-term growth challenges, including declining operating profit and a high dividend yield of 0%.